News
TOI
1.180
+4.42%
0.050
Weekly Report: what happened at TOI last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at TOI last week (0408-0412)?
Weekly Report · 04/15 09:52
Press Release: Jordan McInerney Appointed as Chief Development Officer of The Oncology Institute
Jordan McInerney Appointed as Chief Development Officer of The Oncology Institute Executive Brings Wealth of Experience in Advancing Value-Based Specialty Care Models. The oncology institute, Inc. And its affiliates announced the appointment of Jordan Mc inerney as the new chief development officer effective April 1, 2024. Mc innerney most recently served as the Chief Operations Officer of HOPCo.
Dow Jones · 04/08 12:00
Weekly Report: what happened at TOI last week (0401-0405)?
Weekly Report · 04/08 09:53
The Oncology Institute and Healthly Forge Strategic Alliance to Elevate Cancer Care Access to Healthly Patients Across Southern California
The Oncology Institute, Inc. And Healthly will offer cancer care services to patients in Southern California starting July 1, 2024. Healthly is a rapidly growing healthcare company with over 180 primary care physicians. The partnership aims to deliver comprehensive cancer care to patients across the region.
Barchart · 04/04 07:00
Oncology Institute Unveils Clear Financial Outlook for 2024
TipRanks · 04/03 20:12
Weekly Report: what happened at TOI last week (0325-0329)?
Weekly Report · 04/01 09:53
Oncology Institute’s Balancing Act: Navigating Goodwill Impairment Amid Financial Strains
TipRanks · 03/29 06:02
Oncology Institute Inc reports results for the quarter ended in December - Earnings Summary
Oncology Institute Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 21 cents per share. Revenue rose 20.1% to $85.79 million from a year ago. The average analyst rating on the shares is "strong buy"
Reuters · 03/28 16:33
12 Health Care Stocks Moving In Thursday's Intraday Session
Avalo Therapeutics (NASDAQ:AVTX) stock rose 363.1% to $22.0 during Thursday's regular session. The company's market cap stands at $17.6 million. Biodexa Pharmaceuticals and Ontrak stock increased by 71.82% and 37.66% respectively. Q4 earnings came out today.
Benzinga · 03/28 16:31
TOI Stock Earnings: The Oncology Institute Misses EPS, Beats Revenue for Q4 2023
The Oncology Institute reported earnings per share of -21 cents. The company reported revenue of $85.79 million. This was 4.57% better than the analyst estimate for the company's revenue. The oncology institute reported earnings of -11 cents.
Investorplace · 03/28 00:52
Recap: Oncology Institute Q4 Earnings
Oncology Institute reported its Q4 earnings on March 27. The company missed estimates by -91.0%. The company's revenue was up $14.36 million from the same period last year. Oncologist Institute is expected to report its earnings on Wednesday, March 27, 2024.
Benzinga · 03/27 20:30
The Oncology Institute Q4 2023 GAAP EPS $(0.21) Misses $(0.11) Estimate, Sales $85.788M Beat $82.042M Estimate
The Oncology Institute reported quarterly losses of $0.21 per share. The company reported quarterly sales of $85.788 million which beat the analyst consensus estimate of $82.042 million by 4.57%. The company missed the quarterly sales estimate by 90.91 percent.
Benzinga · 03/27 20:27
*Oncology Institute 4Q Rev $85.8M >TOI
Dow Jones · 03/27 20:12
*Oncology Institute 4Q Loss/Shr 21c >TOI
Dow Jones · 03/27 20:12
Press Release: The Oncology Institute Reports Fourth Quarter and Full Year 2023 Financial Results and Guidance for 2024
The Oncology Institute, Inc. Reports fourth quarter and full year 2023 financial results and guidance for 2024. The company is one of the largest value-based community oncology groups in the United States. ToI signed a full-risk capitated contract in South Florida in the fourth quarter of 2023. Consolidated revenue of $86 million, an increase of 20.1%.
Dow Jones · 03/27 20:05
Press Release: The Oncology Institute Reports -2-
Forward-looking statements are based on various assumptions and are not predictions of actual performance. These statements are subject to a number of risks and uncertainties. TOI's non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles. ToI uses Adjusted EBITDA as a measure of performance.
Dow Jones · 03/27 20:05
Earnings Scheduled For March 27, 2024
Local Bounti is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million. Companies Reporting Before The Bell include REE Automotive and Lands' End. The companies are expected to report earnings for their fourth quarter before the bell.
Benzinga · 03/27 09:02
Earnings Outlook For The Oncology Institute
The Oncology Institute is set to give its latest quarterly earnings report on Wednesday. Analysts estimate the company will report an earnings per share of $-0.11. Last quarter the company missed EPS by $0.06. Shares of the company are up 150.5% over the last 52 weeks.
Benzinga · 03/26 15:01
Oncology Institute Inc <TOI.OQ> expected to post a loss of 11 cents a share - Earnings Preview
Oncology Institute Inc expected to report a 14.9% increase in quarterly revenue to $82.042 million. The company is expected to post a loss of 11 cents a share. The one available analyst rating on the shares is 'strong buy' for the company.
Reuters · 03/25 20:24
More
Webull provides a variety of real-time TOI stock news. You can receive the latest news about The Oncology Institute Inc through multiple platforms. This information may help you make smarter investment decisions.
About TOI
The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at 83 clinic locations across 15 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion and dispensary, radiation, programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. It also provides management services to 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.